Collegium Pharmaceutical (NASDAQ:COLL) Sets New 12-Month Low – Here’s Why

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) hit a new 52-week low on Monday . The stock traded as low as $28.97 and last traded at $29.18, with a volume of 46245 shares trading hands. The stock had previously closed at $29.70.

Analysts Set New Price Targets

A number of analysts have recently weighed in on COLL shares. HC Wainwright increased their price objective on Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, September 5th. Piper Sandler reissued a “neutral” rating and issued a $37.00 price target on shares of Collegium Pharmaceutical in a report on Friday, October 11th. Finally, StockNews.com cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 23rd. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $42.60.

Collegium Pharmaceutical Trading Down 1.6 %

The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. The firm has a market capitalization of $942.02 million, a PE ratio of 12.59 and a beta of 0.80. The stock’s 50-day simple moving average is $32.48 and its 200-day simple moving average is $34.32.

Hedge Funds Weigh In On Collegium Pharmaceutical

A number of institutional investors have recently bought and sold shares of COLL. Foundry Partners LLC purchased a new position in shares of Collegium Pharmaceutical during the 2nd quarter worth approximately $492,000. Penserra Capital Management LLC purchased a new stake in Collegium Pharmaceutical in the third quarter worth $757,000. Squarepoint Ops LLC raised its holdings in Collegium Pharmaceutical by 194.5% in the second quarter. Squarepoint Ops LLC now owns 110,338 shares of the specialty pharmaceutical company’s stock worth $3,553,000 after purchasing an additional 72,874 shares in the last quarter. BOKF NA purchased a new position in Collegium Pharmaceutical during the second quarter valued at $490,000. Finally, Renaissance Technologies LLC lifted its position in Collegium Pharmaceutical by 8.0% during the second quarter. Renaissance Technologies LLC now owns 1,531,498 shares of the specialty pharmaceutical company’s stock valued at $49,314,000 after buying an additional 113,300 shares during the period.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.